These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 34281456)
1. Dapagliflozin for the treatment of type 2 diabetes mellitus - an update. Nicholson MK; Ghazal Asswad R; Wilding JP Expert Opin Pharmacother; 2021 Dec; 22(17):2303-2310. PubMed ID: 34281456 [TBL] [Abstract][Full Text] [Related]
2. Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes. Fioretto P; Avogaro A Expert Opin Pharmacother; 2017 Apr; 18(5):517-527. PubMed ID: 28277831 [TBL] [Abstract][Full Text] [Related]
3. Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus. Carlson CJ; Santamarina ML Expert Opin Drug Saf; 2016 Oct; 15(10):1401-12. PubMed ID: 27449721 [TBL] [Abstract][Full Text] [Related]
4. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors. Rahelić D; Javor E; Lucijanić T; Skelin M Ann Med; 2017 Feb; 49(1):51-62. PubMed ID: 27535028 [TBL] [Abstract][Full Text] [Related]
5. Dapagliflozin: A Sodium Glucose Cotransporter 2 Inhibitor for the Treatment of Diabetes Mellitus. Davis PN; Ndefo UA; Oliver A J Pharm Pract; 2016 Apr; 29(2):165-71. PubMed ID: 25609661 [TBL] [Abstract][Full Text] [Related]
6. Sodium-glucose cotransporter 2 inhibitors for the management of type 2 diabetes. Siamashvili M; Davis SN Expert Opin Pharmacother; 2021 Nov; 22(16):2181-2198. PubMed ID: 34388350 [TBL] [Abstract][Full Text] [Related]
7. A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus. Avogaro A; Giaccari A; Fioretto P; Genovese S; Purrello F; Giorgino F; Del Prato S Expert Rev Clin Pharmacol; 2017 Jul; 10(7):763-772. PubMed ID: 28431476 [TBL] [Abstract][Full Text] [Related]
8. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure. Soga F; Tanaka H; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI Cardiovasc Diabetol; 2018 Oct; 17(1):132. PubMed ID: 30296931 [TBL] [Abstract][Full Text] [Related]
9. Combination therapy for type 2 diabetes: dapagliflozin plus metformin. Tan X; Hu J Expert Opin Pharmacother; 2016; 17(1):117-26. PubMed ID: 26567559 [TBL] [Abstract][Full Text] [Related]
10. Dapagliflozin for the treatment of chronic kidney disease. Kurata Y; Nangaku M Expert Rev Endocrinol Metab; 2022 Jul; 17(4):275-291. PubMed ID: 35822873 [TBL] [Abstract][Full Text] [Related]
11. Dapagliflozin for the treatment of type 2 diabetes. Abdul-Ghani MA; DeFronzo RA Expert Opin Pharmacother; 2013 Aug; 14(12):1695-703. PubMed ID: 23800130 [TBL] [Abstract][Full Text] [Related]
12. Antidiabetic Drug Approved to Reduce Risk of Kidney Disease. Aschenbrenner DS Am J Nurs; 2021 Sep; 121(9):25. PubMed ID: 34438427 [TBL] [Abstract][Full Text] [Related]
14. Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes. Vivian EM Am J Health Syst Pharm; 2015 Mar; 72(5):361-72. PubMed ID: 25694411 [TBL] [Abstract][Full Text] [Related]
15. [Dapagliflozin: Beyond glycemic control in the treatment of type 2 diabetes mellitus]. Sanz-Serra P; Pedro-Botet J; Flores-Le Roux JA; Benaiges D; Chillarón JJ Clin Investig Arterioscler; 2015; 27(4):205-11. PubMed ID: 25648671 [TBL] [Abstract][Full Text] [Related]
16. Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure. Tanaka H; Soga F; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI Cardiovasc Diabetol; 2020 Jan; 19(1):6. PubMed ID: 31910853 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, pharmacodynamics and clinical efficacy of dapagliflozin for the treatment of type 2 diabetes. Maranghi M; Carnovale A; Durante C; Tarquini G; Tiseo G; Filetti S Expert Opin Drug Metab Toxicol; 2015 Jan; 11(1):125-37. PubMed ID: 25418019 [TBL] [Abstract][Full Text] [Related]
18. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. Furtado RHM; Bonaca MP; Raz I; Zelniker TA; Mosenzon O; Cahn A; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Ruff CT; Nicolau JC; Gause-Nilsson IAM; Fredriksson M; Langkilde AM; Sabatine MS; Wiviott SD Circulation; 2019 May; 139(22):2516-2527. PubMed ID: 30882239 [TBL] [Abstract][Full Text] [Related]
19. Dapagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes. Demaris KM; White JR Drugs Today (Barc); 2013 May; 49(5):289-301. PubMed ID: 23724409 [TBL] [Abstract][Full Text] [Related]
20. Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. Berg DD; Wiviott SD; Scirica BM; Gurmu Y; Mosenzon O; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Johanson P; Johansson PA; Langkilde AM; Raz I; Braunwald E; Sabatine MS Circulation; 2019 Nov; 140(19):1569-1577. PubMed ID: 31474116 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]